Clinical Trials Logo

Lymphoma, Large-Cell clinical trials

View clinical trials related to Lymphoma, Large-Cell.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01118845 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Start date: April 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy of SyB L-0501 in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.

NCT ID: NCT00546793 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

Start date: January 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if a subcutaneous (SC) dosing schedule of veltuzumab can be established in NHL or CLL patients and to confirm the safety and efficacy of veltuzumab that was previously established when administered intravenously.

NCT ID: NCT00187070 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Large Cell Lymphoma Pilot Study III

Start date: December 1997
Phase: N/A
Study type: Interventional

The main purpose of this study is to find out if it is feasible to deliver a multi-agent chemotherapy regimen which features a shorter, more intensive, immunophenotype-directed approach, and includes an intensification phase with hematopoietic stem cell support for children with large cell lymphoma

NCT ID: NCT00051597 Completed - Lymphoma, B-Cell Clinical Trials

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Start date: n/a
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate a multi-dose regimen of SGN-30, a novel chimeric monoclonal antibody (mAb), in patients with refractory or recurrent CD30+ hematologic malignancies. This is a single-arm, open-label phase I/II study designed to define the toxicity profile, pharmacokinetic (PK) profile, and anti-tumor activity of a multi-dose regimen of SGN-30 in patients with refractory or recurrent CD30+ hematologic malignancies. The phase I study will be a modified dose escalation of SGN-30. Based on preclinical pharmacology and toxicokinetics (TK) and the first use in human single-dose phase I study, SGN-30 will be administered on a weekly schedule. An initial dose of 2 mg/kg will escalate until the maximum tolerated dose (MTD) has been reached or until a weekly dose of 12 mg/kg is achieved.